Extrachromosomal plasmid vectors for gene therapy

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 4, 2002, Pages 299-305

  Stoll, Stephanie M ^a   Calos, Michele P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Extrachromosomal; Gene delivery; Gene therapy; Genomic DNA; Long term expression; Non viral vector

Indexed keywords

BLOOD CLOTTING FACTOR 8; DNA VACCINE; DYSTROPHIN; EXTRACHROMOSOMAL DNA; GENOMIC DNA; LIPOSOME; PLASMID DNA; PLASMID VECTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; DUCHENNE MUSCULAR DYSTROPHY; ELECTROPORATION; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; GENE THERAPY; GENETIC STABILITY; HEMOPHILIA B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; TRANSGENE; ULTRASOUND; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ELECTROPORATION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; PLASMIDS; VACCINES, DNA;

ADENO-ASSOCIATED VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036705432     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Verma IM, Somia N: Gene therapy - promises, problems and prospects. Nature (1997) 389:239-242.
2. Thyagarajan B, Phillips JE, Calos MP: Gene delivery by viruses. In: Encyclopedia of Life Sciences (2001), Nature Publishing Group, London, UK. http://www.els.net
3. 1-antitrypsin in mice. Mol Therapy (2001) 4:122-129.
4. 1-antitrypsin with negligible toxicity. Hum Gene Ther (1998) 9:2709-2716.
5. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S: Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet (1998) 18:180-183.
6. Wade-Martins R, White RE, Kimura H, Cook PR, James MR: Stable correction of a genetic deficiency in human cells by an episome carrying a 115 kb genomic transgene. Nat Biotechnol (2000) 18:1311-1314.
7. Huertas D, Howe S, McGuigan A, Huxley C: Expression of the human CFTR gene from episomal oriP-EBNA1-YACs in mouse cells. Hum Mol Genet (2000) 9:617-629.
8. Manson AL, Trezise AE, MacVinish LJ, Kasschau KD, Birchall N, Episkopou V, Vassaux G, Evans MJ, Colledge WH, Cuthbert AW, Huxley C: Complementation of null CF mice with a human CFTR YAC transgene. EMBO J (1997) 16:4238-4249.
9. Miao CH, Ohashi K, Patijn GA, Meuse L, Ye X, Thompson AR, Kay MA: Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Therapy (2000) 1:522-532.
10. Miao CH, Thompson AR, Loeb K, Ye X: Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Therapy (2001) 3:947-957.
11. Chen ZY, Yant SR, He CY, Meuse L, Shen S, Kay MA: Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol Therapy (2001) 3:403-410.
12. 1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene Ther(2000) 7:1344-1349.
13. Gill DR, Smyth SE, Goddard CA, Pringle IA, Higgins CF, Colledge WH, Hyde SC: Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1α promoter. Gene Ther (2001) 8:1539-1546.
14. Rawlins DR, Milman G, Hayward SD, Hayward GS: Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell (1985) 42:859-868.
15. Harris A, Young BD, Griffin BE: Random association of Epstein-Barr virus genomes; with host cell metaphase chromosomes in Burkitt's lymphoma-derived cell lines. J Virol (1985) 56:328-332.
16. Yates J, Warren N, Reisman D, Sugden B: A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA (1984) 81:3806-3810.
17. Yates JL, Warren N, Sugden B: Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (1985) 313:812-815.
18. Reisman D, Yates J, Sugden B: A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol (1985) 5:1822-1832.
19. Mizuguchi H, Hosono T, Hayakawa T: Long-term replication of Epstein-Barr virus-derived episomal vectors in the rodent cells. FEBS Lett (2000) 472:173-178.
20. Krysan PJ, Smith JG, Calos MP: Autonomous replication in human cells of multimers of specific human and bacterial DNA sequences. Mol Cell Biol (1993) 13:2688-2696.
21. Krysan PJ, Haase SB, Calos MP: Isolation of human sequences that replicate autonomously in human cells. Mol Cell Biol (1989) 9:1026-1033.
22. Tsukamoto H, Wells D, Brown S, Serpente P, Strong P, Drew J, Inui K, Okada S, Dickson G: Enhanced expression of recombinant dystrophin following intramuscular injection of Epstein-Barr virus (EBV)-based mini-chromosome vectors in mdx mice. Gene Ther (1999) 6:1331-1335.
23. Otomo T, Yamamoto S, Morishita R, Kaneda Y: EBV replicon vector system enhances transgene expression in vivo: Applications to cancer gene therapy. J Gene Med (2001) 3:345-352.
24. Reisman D, Sugden B: Trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol (1986) 6:3838-3846.
25. Kaneda Y, Saeki Y, Nakabayashi M, Zhou WZ, Kaneda MW, Morishita R: Enhancement of transgene expression by cotransfection of oriP plasmid with EBNA-1 expression vector. Hum Gene Ther (2000) 11:471-479.
26. Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, Gooi HC, Goddard CA, Hannavy K, Smyth SE, Egan JJ et al: Repeat administration of DNA/liposomes; to the nasal epithelium of patients with cystic fibrosis. Gene Ther (2000) 7:1156-1165.
27. Krieg AM: Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med (1999) 1:56-63.
28. Yew NS, Zhao H, Przybylska M, Wu IH, Tousignant JD, Scheule RK, Cheng SH: CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Therapy (2002) 5:731-738.
29. Yew NS, Zhao H, Wu IH, Song A, Tousignant JD, Przybylska M, Cheng SH: Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol Therapy (2000) 1:255-262.
30. Liu F, Song Y, Liu D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther (1999) 6:1258-1266.
31. Zhang G, Budker V, Wolff JA: High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther (1999) 10:1735-1737.
32. Yang J, Dai C, Liu Y: Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther (2001) 8:1470-1479.
33. Vorup-Jensen T, Jensen UB, Liu H, Kawasaki T, Uemura K, Thiel S, Dagnaes-Hansen F, Jensen TG: Tail-vein injection of mannan-binding lectin DNA leads to high expression levels of multimeric protein in liver. Mol Therapy (2001) 3:867-874.
34. Zhang G, Budker V, Williams P, Subbotin V, Wolff JA: Efficient expression of naked DNA delivered intraarterially to limb muscles of nonhuman primates. Hum Gene Ther (2001) 12:427-438.
35. Liu F, Huang L: Noninvasive gene delivery to the liver by mechanical massage. Hepatology (2002) 35:1314-1319.
36. Liu F, Nishikawa M, Clemens PR, Huang L: Transfer of full-length Dmd to the diaphragm muscle of Dmd(mdx/mdx) mice through systemic administration of plasmid DNA. Mol Therapy (2001) 4:45-51.
37. Somiari S, Glasspool-Malone J, Drabick JJ, Gilbert RA, Heller R, Jaroszeski MJ, Malone RW: Theory and in vivo application of electroporative gene delivery. Mol Therapy (2000) 2:178-187.
38. Lucas ML, Heller R: Immunomodulation by electrically enhanced delivery of plasmid DNA encoding IL-12 to murine skeletal muscle. Mol Therapy (2001) 3:47-53.
39. Lucas ML, Heller L, Coppola D, Heller R: IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Therapy (2002) 5:668-675.
40. Heller R, Schultz J, Lucas ML, Jaroszeski MJ, Heller LC, Gilbert RA, Moelling K, Nicolau C: Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation. DNA Cell Biol (2001) 20:21-26.
41. Liu F, Huang L: A syringe electrode device for simultaneous injection of DNA and electrotransfer. Mol Therapy (2002) 5:323-328.
42. Yin D, Tang JG: Gene therapy for streptozotocin-induced diabetic mice by electroporational transfer of naked human insulin precursor DNA into skeletal muscle in vivo. FEBS Lett (2001) 495:16-20.
43. Vilquin JT, Kennel PF, Paturneau-Jouas M, Chapdelaine P, Boissel N, Delaere P, Tremblay JP, Scherman D, Fiszman MY, Schwartz K: Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Ther (2001) 8:1097-1107.
44. Huber PE, Pfisterer P: In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther (2000) 7:1516-1525.
45. Taniyama Y, Tachibana K, Hiraoka K, Aoki M, Yamamoto S, Matsumoto K, Nakamura T, Ogihara T, Kaneda Y, Morishita R: Development of safe and efficient novel nonviral gene transfer using ultrasound: Enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther (2002) 9:372-380.
46. Affleck DG, Yu L, Bull DA, Bailey SH, Kim SW: Augmentation of myocardial transfection using TerplexDNA: A novel gene delivery system. Gene Ther (2001) 8:349-353.
47. Densmore CL, Orson FM, Xu B, Kinsey BM, Waldrep JC, Hua P, Bhogal B, Knight V: Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Therapy (2000) 1:180-188.
48. Mahato RI, Lee M, Han S, Maheshwari A, Kim SW: Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Mol Therapy (2001) 4:130-138.
49. Tam P, Monck M, Lee D, Ludkovski O, Leng EC, Clow K, Stark H, Scherrer P, Graham RW, Cullis PR: Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther (2000) 7:1867-1874.
50. Déas O, Angevin E, Cherbonnier C, Senik A, Charpentier B, Levillain JP, Oosterwijk E, Hirsch F, Dürrbach A: In vivo-targeted gene delivery using antibody-based nonviral vector. Hum Gene Ther (2002) 13:1101-1114.
51. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K et al: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 290:486-492.
52. Peng HJ, Su SN, Chang ZN, Chao PL, Kuo SW, Tsai LC: Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Der f 11. Vaccine (2002) 20:1761-1768.
53. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA et al: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 292:69-74.
54. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG: Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med (2002) 8:415-419.